Advanced search
1 file | 346.36 KB

Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results

(2013) BLOOD. 121(13). p.2415-2423
Author
Organization
Abstract
The aim of our study was to analyze the factors contributing to heterogeneity of prognosis in patients with hyperdiploidy>50 chromosomes (HD>50), a group of B-cell precursor acute lymphoblastic leukemia with favorable outcome. The 541 HD>50 patients registered prospectively in the 58951 European Organisation for Research and Treatment of Cancer (EORTC) Children's Leukemia Group (CLG) trial, identified by karyotype (446 patients) and by DNA index (DI) (490 patients), had a 6-year event-free survival (EFS) of 89.0% (standard error [SE] = 1.5%) and a 6-year overall survival (OS) of 95.9% (SE = 0.9%). The strongest prognostic factor was the modal number of chromosomes (MNC): the 6-year EFS of 51-53, 54-57, and 58-66 MNC groups were 80%, 89%, and 99%, respectively (P < .0001). Ploidy assessed by DI was also a favorable factor: the higher the DI, the better the outcome. The 6-year EFS of the 3 subgroups of DI < 1.16/>= 1.16-<1.24/>= 1.24 were 83%, 90%, and 95%, respectively (P = .009). All usual combinations of trisomies (chromosomes 4, 10, 17, 18) were significant favorable factors but had lower EFS when MNC was lower than 58. In multivariate analysis, MNC remained the strongest factor. Consequently, the best indicator for excellent outcome was ploidy assessed by karyotype because patients with 58-66 chromosomes stood every chance of being cured (OS of 100% at 6-year follow-up) with less-intensive therapy. This trial was registered at www.clinicaltrials.gov as #NCT00003728. Registered: http://www.eortc.org/, http://clinicaltrials.gov/show/NCT00003728.
Keywords
MINIMAL RESIDUAL DISEASE, ONCOLOGY-GROUP POG, CANCER-GROUP CCG, PROGNOSTIC IMPORTANCE, PHASE-3 TRIAL, CHILDREN, RISK, CLASSIFICATION, REARRANGEMENTS, HETEROGENEITY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 346.36 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Dastugue, Nicole, Stefan Suciu, Geneviève Plat, Franki Speleman, Hélène Cavé, Sandrine Girard, Marleen Bakkus, et al. 2013. “Hyperdiploidy with 58-66 Chromosomes in Childhood B-acute Lymphoblastic Leukemia Is Highly Curable: 58951 CLG-EORTC Results.” Blood 121 (13): 2415–2423.
APA
Dastugue, N., Suciu, S., Plat, G., Speleman, F., Cavé, H., Girard, S., Bakkus, M., et al. (2013). Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. BLOOD, 121(13), 2415–2423.
Vancouver
1.
Dastugue N, Suciu S, Plat G, Speleman F, Cavé H, Girard S, et al. Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. BLOOD. 2013;121(13):2415–23.
MLA
Dastugue, Nicole, Stefan Suciu, Geneviève Plat, et al. “Hyperdiploidy with 58-66 Chromosomes in Childhood B-acute Lymphoblastic Leukemia Is Highly Curable: 58951 CLG-EORTC Results.” BLOOD 121.13 (2013): 2415–2423. Print.
@article{4267483,
  abstract     = {The aim of our study was to analyze the factors contributing to heterogeneity of prognosis in patients with hyperdiploidy{\textrangle}50 chromosomes (HD{\textrangle}50), a group of B-cell precursor acute lymphoblastic leukemia with favorable outcome. The 541 HD{\textrangle}50 patients registered prospectively in the 58951 European Organisation for Research and Treatment of Cancer (EORTC) Children's Leukemia Group (CLG) trial, identified by karyotype (446 patients) and by DNA index (DI) (490 patients), had a 6-year event-free survival (EFS) of 89.0\% (standard error [SE] = 1.5\%) and a 6-year overall survival (OS) of 95.9\% (SE = 0.9\%). The strongest prognostic factor was the modal number of chromosomes (MNC): the 6-year EFS of 51-53, 54-57, and 58-66 MNC groups were 80\%, 89\%, and 99\%, respectively (P {\textlangle} .0001). Ploidy assessed by DI was also a favorable factor: the higher the DI, the better the outcome. The 6-year EFS of the 3 subgroups of DI {\textlangle} 1.16/{\textrangle}= 1.16-{\textlangle}1.24/{\textrangle}= 1.24 were 83\%, 90\%, and 95\%, respectively (P = .009). All usual combinations of trisomies (chromosomes 4, 10, 17, 18) were significant favorable factors but had lower EFS when MNC was lower than 58. In multivariate analysis, MNC remained the strongest factor. Consequently, the best indicator for excellent outcome was ploidy assessed by karyotype because patients with 58-66 chromosomes stood every chance of being cured (OS of 100\% at 6-year follow-up) with less-intensive therapy. This trial was registered at www.clinicaltrials.gov as \#NCT00003728. Registered: http://www.eortc.org/, http://clinicaltrials.gov/show/NCT00003728.},
  author       = {Dastugue, Nicole and Suciu, Stefan and Plat, Genevi{\`e}ve and Speleman, Franki and Cav{\'e}, H{\'e}l{\`e}ne and Girard, Sandrine and Bakkus, Marleen and Pag{\`e}s, Marie Pierre and Yakouben, Karima and Nelken, Brigitte and Uyttebroeck, Anne and Gervais, Carine and Lutz, Patrick and Teixeira, Manuel R and Heimann, Pierre and Ferster, Alice and Rohrlich, Pierre and Collonge, Marie Agn{\`e}s and Munzer, Martine and Luquet, Isabelle and Boutard, Patrick and Sirvent, Nicolas and Karrasch, Matthias and Bertrand, Yves and Benoit, Yves},
  issn         = {0006-4971},
  journal      = {BLOOD},
  language     = {eng},
  number       = {13},
  pages        = {2415--2423},
  title        = {Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results},
  url          = {http://dx.doi.org/10.1182/blood-2012-06-437681},
  volume       = {121},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: